Affiliations: [a] Department of Biochemistry, M.V. Lomonosov Moscow State University, Moscow, Russia | [b] Department of Biomedical Sciences, Ohio University, Athens, OH, USA | [x] Department of Biochemistry, M.V. Lomonosov Moscow State University, Moscow, Russia | [y] Department of Biomedical Sciences, Ohio University, Athens, OH, USA
Correspondence:
[*]
Corresponding author: Alexander A. Boldyrev, Department of Biochemistry, M.V. Lomonosov Moscow State University, 119992 Moscow, Russia. Tel./Fax: +7 495 939 1398; E-mail: alexander.boldyrev@gmail.com.
Abstract: Homocysteine (HC) and its derivatives may be involved in the etiology of Alzheimer's Disease (AD), although the precise mechanisms by which these compounds could cause cellular pathology are still unclear. Because interactions of HC with glutamate receptors have been implicated in AD, receptor-mediated effects of HC and homocysteic acid (HCA) on neurons and lymphocytes have been analyzed. Activation of glutamate receptors by these compounds has been shown to increase intracellular calcium and free radical levels in both types of cells, which may serve as a signal for development of apoptosis. Activation of group III metabotropic glutamate receptors stimulates, whereas activation of group I and group II metabotropic glutamate receptors prevent, the excitotoxic action of HC and HCA. These effects may contribute to the neuronal pathology and immunosenescence that occur in AD. It is proposed that selective agonists of metabotropic glutamate receptors that counter the effects of HC and its derivatives may be used for correction of neuronal and immune cell metabolism in vivo under the conditions of hyperhomocysteinemia, which can occur in AD.
